Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.56 |
| ▸ | CDC7 | O00311 | 11/20 | 0.52 |
| ▸ | DBF4 | Q9UBU7 | 11/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | CRHBP | P24387 | 1/20 | 0.49 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15049164 | 0.92 | TRPM8 (0.53) | TRPM8CDC7DBF4MAPTMEN1 | |
| SCHEMBL15049127 | 0.83 | TRPM8 (0.62) | TRPM8CDC7DBF4MAPTMEN1 | |
| SCHEMBL15049377 | 0.82 | MAPT (0.72) | TRPM8CDC7DBF4MAPTMEN1 | |
| SCHEMBL28245823 | 0.82 | CDC7 (0.57) | TRPM8CDC7DBF4MAPTMEN1 | |
| SCHEMBL15049292 | 0.81 | TRPM8 (0.64) | TRPM8CDC7DBF4MAPTMEN1 | |
| SCHEMBL15049121 | 0.78 | TRPM8 (0.67) | TRPM8CDC7DBF4MAPTMEN1 | |
| SCHEMBL15049067 | 0.77 | MAPT (0.50) | TRPM8CDC7DBF4MAPTMEN1 | |
| SCHEMBL28245821 | 0.74 | CDC7 (0.57) | TRPM8CDC7DBF4MAPTMEN1 | |
| SCHEMBL15049085 | 0.74 | MAPT (0.72) | TRPM8CDC7DBF4MAPTMEN1 | |
| SCHEMBL15049166 | 0.73 | TRPM8 (0.62) | TRPM8CDC7DBF4MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2793883-B1 | TRPM8 ANTAGONISTS | DOMPE FARM SPA (IT) | 2018-04-18 | — | — | EP | claimed |
| US-9856246-B2 | TRPM8 antagonists | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2018-01-02 | — | — | US | claimed |
| US-20170129881-A1 | TRPM8 ANTAGONISTS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2017-05-11 | — | — | US | claimed |
| US-9585875-B2 | TRPM8 antagonists | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2017-03-07 | — | — | US | claimed |
| US-20140371276-A1 | TRPM8 ANTAGONISTS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2014-12-18 | — | — | US | claimed |
| EP-2793883-A1 | TRPM8 ANTAGONISTS | Dompe' S.p.A. (IT) | 2014-10-29 | — | — | EP | claimed |
| WO-2013092711-A1 | TRPM8 ANTAGONISTS | DOMPE' S.P.A. (IT) | 2013-06-27 | — | — | WO | claimed |
| EP-2606888-A1 | Trpm8 antagonists | Dompe' S.P.A. (IT) | 2013-06-26 | — | — | EP | claimed |
| EP-2793883-B1 | TRPM8 ANTAGONISTS | DOMPE FARM SPA (IT) | 2018-04-18 | — | — | EP | disclosed |
| US-9856246-B2 | TRPM8 antagonists | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2018-01-02 | — | — | US | disclosed |
| US-20170129881-A1 | TRPM8 ANTAGONISTS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2017-05-11 | — | — | US | disclosed |
| US-9585875-B2 | TRPM8 antagonists | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2017-03-07 | — | — | US | disclosed |
| US-20140371276-A1 | TRPM8 ANTAGONISTS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2014-12-18 | — | — | US | disclosed |
| EP-2793883-A1 | TRPM8 ANTAGONISTS | Dompe' S.p.A. (IT) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013092711-A1 | TRPM8 ANTAGONISTS | DOMPE' S.P.A. (IT) | 2013-06-27 | — | — | WO | disclosed |
| EP-2606888-A1 | Trpm8 antagonists | Dompe' S.P.A. (IT) | 2013-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129881-A1 | TRPM8 ANTAGONISTS | TRPM8, TRPM7, TRPM5 | TRPM8 1/4885CDC7 2527/4885DBF4 3635/4885 |
| US-20140371276-A1 | TRPM8 ANTAGONISTS | TRPM8, TRPM7, TRPV1 | TRPM8 1/4885CDC7 3237/4885DBF4 3574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.